These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma. Koprivnikar JL; Cheson BD Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439 [TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibition as a novel therapeutic target in human cancer. Rajkumar SV; Richardson PG; Hideshima T; Anderson KC J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509 [TBL] [Abstract][Full Text] [Related]
30. "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D. Bold R Cancer Invest; 2004; 22(2):328-9. PubMed ID: 15199617 [No Abstract] [Full Text] [Related]
31. Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Lorch JH; Thomas TO; Schmoll HJ Cancer Res; 2007 Jan; 67(2):727-34. PubMed ID: 17234784 [TBL] [Abstract][Full Text] [Related]
33. The role of bortezomib in the treatment of lymphoma. Barr P; Fisher R; Friedberg J Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474 [TBL] [Abstract][Full Text] [Related]
34. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742 [TBL] [Abstract][Full Text] [Related]
35. The role of proteasome in malignant diseases. Moran E; Nencioni A J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285 [TBL] [Abstract][Full Text] [Related]
36. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Edelman MJ Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930 [TBL] [Abstract][Full Text] [Related]
37. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
38. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. Cvek B; Dvorak Z Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411 [TBL] [Abstract][Full Text] [Related]
39. Macrocyclic proteasome inhibitors. Krahn D; Ottmann C; Kaiser M Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753 [TBL] [Abstract][Full Text] [Related]